Compare · INCY vs MXCT
INCY vs MXCT
Side-by-side comparison of Incyte Corp. (INCY) and MaxCyte Inc. (MXCT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both INCY and MXCT operate in Biotechnology: Commercial Physical & Biological Resarch (Health Care), so they compete in similar markets.
- INCY is the larger of the two at $23.42B, about 176.3x MXCT ($132.8M).
- INCY has been more active in the news (21 items in the past 4 weeks vs 9 for MXCT).
- INCY has more recent analyst coverage (25 ratings vs 11 for MXCT).
- Company
- Incyte Corp.
- MaxCyte Inc.
- Price
- -
- -
- Market cap
- $23.42B
- $132.8M
- 1M return
- -
- +9.73%
- 1Y return
- -
- -38.92%
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- Biotechnology: Commercial Physical & Biological Resarch
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- News (4w)
- 21
- 9
- Recent ratings
- 25
- 11
Incyte Corp.
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor for the treatment of adults; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a drug that is in Phase III clinical trial for steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase III clinical trial to treat naïve chronic GVHD; and pemigatinib that is in Phase II clinical trial for treating bladder cancer, cholangiocarcinoma, 8p11 myeloproliferative syndrome, and Tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, the company develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; and Cellenkos, Inc., as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.
MaxCyte Inc.
MaxCyte, Inc. operates as a cell-based therapies and life sciences company in the United States and internationally. Its transfection systems include MaxCyte STX, a scalable transfection system that uses flow electroporation technology for the engineering of cells for a range of applications; MaxCyte VLX, an instrument for large volume cell-engineering; and MaxCyte GT, a non-viral cell-engineering technology designed for clinical use. The company also provides single use sterile processing assemblies; and proprietary electroporation buffers; and ExPERT brand series of instruments and consumables, as well as insourcing services. In addition, it develops CARMA, a novel and proprietary technology for the development of non-viral, human messenger RNA-based, chimeric antigen receptor or T-cell receptor redirected immune cell therapies. The company licenses and sells its instruments and technology; and sells its products to drug developers and biopharmaceutical companies. It has a clinical and commercial license agreement with Allogene Therapeutics, Inc. The company was founded in 1998 and is headquartered in Gaithersburg, Maryland.
Latest INCY
- Incyte Data to Be Highlighted in Four Rapid Oral Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 Support Efforts to Improve Outcomes in Difficult-to-Treat Cancers
- President, Global Head of R&D Cagnoni Pablo J covered exercise/tax liability with 22,919 shares, decreasing direct ownership by 10% to 217,929 units (SEC Form 4) (tax withholding)
- EVP & Chief Scientific Officer Mayes Patrick A covered exercise/tax liability with 1,949 shares, decreasing direct ownership by 3% to 57,712 units (SEC Form 4) (tax liability)
- Principal Accounting Officer Tray Thomas covered exercise/tax liability with 1,790 shares, decreasing direct ownership by 9% to 18,865 units (SEC Form 4) to cover withholding tax
- CMO & Head of Late-Stage Dev. Stein Steven H sold $3,192,193 worth of shares (28,237 units at $113.05) and covered exercise/tax liability with 24,918 shares, decreasing direct ownership by 70% to 22,995 units (SEC Form 4) (for tax liability)
- EVP, Head of U.S. Commercial Issa Mohamed Khairie covered exercise/tax liability with 1,099 shares, decreasing direct ownership by 2% to 65,033 units (SEC Form 4) to satisfy withholding tax
- Incyte Presents Phase 1/2 Multidose Data for VGA039 (Latarcibart) at ISTH 2026, Showing Substantial Bleed Reductions in Patients with all Von Willebrand Disease Types
- Incyte to Report Second Quarter Financial Results
- Chief Executive Officer Meury William covered exercise/tax liability with 4,779 shares, decreasing direct ownership by 3% to 156,322 units (SEC Form 4) (withholding tax)
- EVP & Chief Scientific Officer Mayes Patrick A covered exercise/tax liability with 350 shares, decreasing direct ownership by 0.58% to 59,661 units (SEC Form 4) to cover taxes
Latest MXCT
- MaxCyte to Report Second Quarter 2026 Financial Results on August 12, 2026
- Director Johnston John Joseph was granted 30,421 shares, increasing direct ownership by 18% to 201,581 units (SEC Form 4)
- Director Hemrajani Rekha was granted 30,421 shares, increasing direct ownership by 76% to 70,314 units (SEC Form 4)
- Director Erck Stanley C was granted 30,421 shares, increasing direct ownership by 8% to 428,749 units (SEC Form 4)
- Director Douglas Richard was granted 30,421 shares, increasing direct ownership by 13% to 260,998 units (SEC Form 4)
- Director Collins Cynthia was granted 30,421 shares, increasing direct ownership by 38% to 111,310 units (SEC Form 4)
- Director Brooke William W was granted 30,421 shares, increasing direct ownership by 20% to 181,300 units (SEC Form 4)
- Director Balthrop Patrick J was granted 30,421 shares, increasing direct ownership by 60% to 80,998 units (SEC Form 4)
- Director Al-Wakeel Yasir B. was granted 30,421 shares, increasing direct ownership by 60% to 80,998 units (SEC Form 4)
- MaxCyte Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders